title: An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
abstract: Existing therapeutic options for management of essential tremor are frequently limited by poor efficacy and adverse effects. Likely the most potent tremor suppressant used is ethanol, although its use is prohibitive due to a brief therapeutic window, and the obvious implications of excessive alcohol use. Longer-chain alcohols have been shown to suppress tremor in harmaline animal models, and appear to be safe and well tolerated in 2 prior studies in humans. Here we report on the findings of a phase I/II study of 1-octanol designed to explore pharmacokinetics, efficacy, and safety. The most significant finding was the identification of octanoic acid as the product of rapid 1-octanol metabolism. Furthermore, the temporal profile of efficacy closely matches the plasma concentration of octanoic acid. Therefore, these findings identify a novel class of compound (e.g., carboxylic acids) with tremor suppressive properties in ET. Administration of 1-octanol also appears to be safe based on various measures collected. Essential tremor (ET) is the most common tremor disorder, with tremors occurring during static posturing or movement. These tremors are known to briefly improve in many cases after alcohol (ethanol) consumption. Two previous studies of a longer chain alcohol, 1-octanol, have demonstrated longer duration tremor-suppressive effects without the occurrence of intoxication. The aim of this study was to characterize the pharmacokinetics of 1-octanol and its primary metabolite octanoic acid using two formulations, along with additional safety and efficacy measures. Participants with proven ethanol-responsive ET were recruited into 1 of 2 parts: (part A) a dose escalation study (1-64 mg/kg; n = 4), and (part B) a fixed dose (64 mg/kg; n = 10) balanced, open-label crossover design. Two participants in part B then completed an exploratory part C evaluating 128 mg/kg.Plasma samples were collected at 10 intervals during a 6-hour period postingestion. Efficacy was assessed using spirography, whereas safety was assessed with electrocardiograms, vital signs, adverse effects surveys, and an intoxication assessment. Plasma concentrations of 1-octanol were detectable at low levels whereas octanoic acid (OA) concentrations were approximately 100-fold higher. The half-life of OA was 87.6 minutes. This was matched by a clinical reduction in tremor severity of 32% at 90 minutes, assessed using spirography. The safety profile was favorable, with the most commonly reported adverse effect being dysgeusia (38%). Early detection and higher plasma concentrations of OA are a product of rapid metabolism of 1-octanol.OA pharmacokinetics mirrored the timing of clinical improvement. These findings provide preliminary evidence for a new class of compound that may be effective in the treatment of ET.
authors: Department of Neurology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. fnahab@med.miami.edu
authors: Fatta B
authors: FB
authors: Nahab
authors: Loretta
authors: L
authors: Wittevrongel
authors: Dominic
authors: D
authors: Ippolito
authors: Camilo
authors: C
authors: Toro
authors: George J
authors: GJ
authors: Grimes
authors: Judith
authors: J
authors: Starling
authors: Gopal
authors: G
authors: Potti
authors: Dietrich
authors: D
authors: Haubenberger
authors: Daniel
authors: D
authors: Bowen
authors: Peter
authors: P
authors: Buchwald
authors: Chuanhui
authors: C
authors: Dong
authors: Daniel
authors: D
authors: Kalowitz
authors: Mark
authors: M
authors: Hallett
references: Neurology. 1984 Feb;34(2):221-2
references: 6538013
references: J Pharmacol Exp Ther. 1981 Sep;218(3):669-75
references: 7264950
references: Pflugers Arch. 1989 May;414(1):31-6
references: 2542888
references: Life Sci. 1984 Jan 2;34(1):49-56
references: 6319933
references: Ann Neurol. 1994 Jun;35(6):717-23
references: 8210229
references: Neurology. 2004 Jan 13;62(1):122-4
references: 14718713
references: Acta Pathol Jpn. 1991 Jun;41(6):405-13
references: 1950560
references: Biochim Biophys Acta. 1975 Mar 28;384(1):1-11
references: 165828
references: Neurology. 2004 Jun 22;62(12):2320-2
references: 15210907
references: Dig Dis Sci. 2002 Jul;47(7):1554-7
references: 12141816
references: Food Chem Toxicol. 2000 Jan;38(1):79-98
references: 10685018
references: Neuropharmacology. 1978 Jul;17(7):451-61
references: 567755
references: J Appl Physiol. 1964 Mar;19:335-7
references: 14155309
references: Neurology. 2000;54(11 Suppl 4):S7
references: 10854345
references: Muscle Nerve. 2001 Jun;24(6):716-35
references: 11360255
references: Mov Disord. 2011 Sep;26(11):2073-80
references: 21714004
references: N Engl J Med. 2001 Sep 20;345(12):887-91
references: 11565522